Lumida
/ABBV
⌘K
AbbVie Inc

AbbVie Inc

ABBV
$254.49USD↑+0.04%+0.10 today

MARKET CAP

449.6B

P/E (TTM)

25.0x

FWD P/E

16.4x

DAY RANGE

$254 – $261

52W RANGE

$185
$262

AI Summary

Stalk
StalkMedium

ABBV remains in Stage 2 advancing corrective reset within a longer-term uptrend, driven by an active Parabola pattern signaling steep acceleration but heightened reversal risk. Price is extended above rising EMAs and tagged overbought, suggesting caution. The medium-term bias stays bullish on intact HH/HL structure and EMA support. Short-term timing is neutral; we will stalk for a shallow pullback into the 9/21 EMA cluster before engaging under the Growth at Reasonable Price framework.

  • ↑Q1 adjusted EPS of $2.65 beat guidance by $0.07 on 12.4% YoY revenue growth to $15 billion.
  • ↑Skyrizzy commands over 45% psoriasis market share, boosting immunology revenues.
  • ↓Humira revenues plunged 40.3% YoY after biosimilar launches, eroding cash flow.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

AbbVie Inc. (NYSE: ABBV) is a leading global biopharmaceutical company that focuses on developing innovative treatments across immunology, oncology, neuroscience, and aesthetics. The company has diversified its portfolio to mitigate risks associated with patent expirations, particularly its blockbuster drug Humira, and is now emphasizing growth in complementary therapeutic areas. With a strong commitment to research and development, AbbVie is well-positioned to capitalize on emerging health challenges, particularly in the burgeoning obesity treatment market.

Bull says

  • ↑Q1 adjusted EPS of $2.65 beat guidance by $0.07 on 12.4% YoY revenue growth to $15 billion.
  • ↑Skyrizzy commands over 45% psoriasis market share, boosting immunology revenues.
  • ↑Pending Renvoke and obesity therapy submissions could drive near-term sales lifts.
  • ↑Committed $100 billion of R&D and capacity investment over the next decade.
  • ↑Raised full-year EPS guidance to $14.08–$14.28 indicates stronger earnings outlook.
  • ↑Dividend yield at 0.97% and low volatility profile appeal to defensive investors.

Bear says

  • ↓Humira revenues plunged 40.3% YoY after biosimilar launches, eroding cash flow.
  • ↓Negative growth factor signals potential long-term revenue stagnation.
  • ↓R&D spend is 15.4% of sales, risking margin compression without near-term returns.
  • ↓Proposed drug pricing reforms may pressure U.S. profitability margins.
  • ↓High short interest and investor skepticism limit upside potential.
  • ↓Poor liquidity may hamper large-scale trading without price impact.

Investment themes with ABBV

High Dividend Yield↑ +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM
Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT
Demographics: Elderly Care↓ -0.26%

Services and products for aging population

UCB.BR · JNJ · AZN

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-30-2026neutral

Transcript signals

Bull points

  • We are raising our full-year adjusted earnings per share guidance to between $14.08 and $14.28.
  • We now expect total net revenues of approximately $67.3 billion, an increase of $300 million.
  • We now expect SCIRISI global revenues of $21.6 billion, an increase of $100 million, reflecting demand growth in psoriatic and IBD indications.

Bear points

  • the regulatory application for alopecia areata was recently submitted to the FDA. Approval decisions are anticipated later this year in Europe and Japan and in early 2027 in the U.S.
  • the FDA issued a complete response letter for our Trinibot E application related to manufacturing questions. The CRL did not identify any issues related to safety, efficacy, or labeling of Trinibot E, nor has the FDA requested any additional clinical trials be conducted.
  • Humira global sales were $688 million, down 40.3% on an operational basis, reflecting biosimilar competition and in line with our expectations.
Read full transcript analysis ›